During the past decade, Retina Institute of California conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 4 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 4 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Retina Institute of California" are "Retinal Vein Occlusion" (2 trials), "Diabetic Macular Edema" (1 trials), "Geographic Atrophy" (1 trials), "Macula Edema" (1 trials) and "Macular Degeneration" (1 trials). Many other conditions were trialed in "Retina Institute of California" in a lesser frequency.

Most popular intervention types in "Retina Institute of California" are "Drug" (4 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "IVT aflibercept" (2 trials), "Abicipar Pegol" (1 trials), "NGM621" (1 trials), "Ranibizumab" (1 trials) and "SC CLS-TA" (1 trials). Other intervention names were less common.

The vast majority of trials in "Retina Institute of California" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Retina Institute of California". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Retina Institute of California, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Institute of California, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".